[go: up one dir, main page]

TNSN90009A1 - Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv - Google Patents

Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv

Info

Publication number
TNSN90009A1
TNSN90009A1 TNTNSN90009A TNSN90009A TNSN90009A1 TN SN90009 A1 TNSN90009 A1 TN SN90009A1 TN TNSN90009 A TNTNSN90009 A TN TNSN90009A TN SN90009 A TNSN90009 A TN SN90009A TN SN90009 A1 TNSN90009 A1 TN SN90009A1
Authority
TN
Tunisia
Prior art keywords
hiv
acylcysteins
treatment
patients
diseases associated
Prior art date
Application number
TNTNSN90009A
Other languages
English (en)
Inventor
Droge Wulf
A Hersenberg Leonard
A Herzenberg Leonore
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of TNSN90009A1 publication Critical patent/TNSN90009A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

ON UTILISE UNE N-(ACYL EN C1-C4) CYSTEINE OU UN DE SES SELS, ET DE PREFERENCE LA N-ACETYLCYSTEINE, POUR PREPARER DES MEDICAMENTS DESTINES A TRAITER DES PATIENTS SOUFFRANT D'UNE INFECTION PAR HIV, DE MANIERE A SOULAGER LES SYMPTOMES ET A RERIMER LA TRANSCRIPTION ET LA PROLIFERATION DE HIV. ON UTILISE EN PARTICULIER DES DERIVES DE N- ACETYLCYSTEINE POUR TRAITER DES PATIENTS SEROPOSITIFS ET DES PATIENTS ATTEINTS DU SIDA SYMPTOMATIQUE ET POUR SOULAGER LES SYMPTOMES TELS QUE LA PERTE DE POIDS ET LA PERTE DE FORCE PHYSIQUE. L'UTILISATION DE COMPOSES DE N-ACETYLCYSTEINE AVEC DES MEDICAMENTS CONNUS QUI AFFECTENT LA PATHOGENESE DES MALADIES INDUITES PAR HIV PEUT AMELIORER L'EFFET DE CES MEDICAMENTS
TNTNSN90009A 1989-01-26 1990-01-24 Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv TNSN90009A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30239689A 1989-01-26 1989-01-26

Publications (1)

Publication Number Publication Date
TNSN90009A1 true TNSN90009A1 (fr) 1991-03-05

Family

ID=23167578

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN90009A TNSN90009A1 (fr) 1989-01-26 1990-01-24 Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv

Country Status (25)

Country Link
US (1) US5607974A (fr)
JP (1) JPH04504570A (fr)
KR (1) KR940002820B1 (fr)
AU (1) AU639686B2 (fr)
BE (1) BE1004168A3 (fr)
CA (3) CA1339256C (fr)
CH (1) CH683499A5 (fr)
DE (1) DE4090165T (fr)
DK (1) DK139191D0 (fr)
FR (1) FR2643557B1 (fr)
GB (1) GB2243296B (fr)
GR (1) GR900100048A (fr)
IE (1) IE62795B1 (fr)
IL (1) IL93162A (fr)
IT (1) IT1237999B (fr)
LU (1) LU87977A1 (fr)
MA (1) MA21739A1 (fr)
MX (1) MX173567B (fr)
NL (1) NL9020094A (fr)
OA (1) OA09503A (fr)
PT (1) PT92949B (fr)
SE (1) SE9101815L (fr)
TN (1) TNSN90009A1 (fr)
WO (1) WO1990008540A1 (fr)
ZA (1) ZA90245B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100914A (pt) * 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
EP0600462A1 (fr) * 1992-12-01 1994-06-08 Nippon Flour Mills Co., Ltd. Inhibiteurs de la transcriptase inverse et agents antiviraux
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
AU7931094A (en) * 1993-10-15 1995-05-04 Jess G. Thoene Prevention of hiv infection
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
TW517089B (en) * 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2005017094A2 (fr) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. Compositions de n-acetyle comme therapie complementaire pour le traitement et la prevention des carences en cysteine/glutathion
WO2005048935A2 (fr) 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methodes pour moduler l'immunite
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070053970A1 (en) * 2005-05-25 2007-03-08 Guilford F T Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4767785A (en) * 1984-01-18 1988-08-30 Michael Georgieff Hypocaloric preparation and intravenous method for hypocaloric treatment of patients
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
EP0158487B1 (fr) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Composition stable d'interleukine-2
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
DE3707127C2 (de) * 1987-03-05 1996-06-20 Zambon Spa Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen
DE3812008A1 (de) * 1987-04-10 1988-10-20 Pfrimmer Pharma Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung

Also Published As

Publication number Publication date
KR910700045A (ko) 1991-03-13
GR900100048A (el) 1991-06-07
IE62795B1 (en) 1995-03-08
GB2243296B (en) 1992-10-21
MX173567B (es) 1994-03-16
US5607974A (en) 1997-03-04
JPH04504570A (ja) 1992-08-13
DK139191A (da) 1991-07-25
PT92949B (pt) 1995-12-29
OA09503A (en) 1992-11-15
CA2045180A1 (fr) 1990-07-27
IT9019141A1 (it) 1991-07-24
IL93162A (en) 1995-03-15
NL9020094A (nl) 1991-10-01
IL93162A0 (en) 1990-11-05
KR940002820B1 (ko) 1994-04-04
GB9112420D0 (en) 1991-07-31
DE4090165T (fr) 1991-11-21
CA1339256C (fr) 1997-08-12
ZA90245B (en) 1990-10-31
BE1004168A3 (fr) 1992-10-06
MA21739A1 (fr) 1990-10-01
PT92949A (pt) 1990-07-31
LU87977A1 (fr) 1992-03-11
DK139191D0 (da) 1991-07-25
IT9019141A0 (it) 1990-01-24
GB2243296A (en) 1991-10-30
SE9101815D0 (sv) 1991-06-13
CA1339070C (fr) 1997-07-29
SE9101815L (sv) 1991-06-13
AU639686B2 (en) 1993-08-05
FR2643557B1 (fr) 1995-02-03
AU4969490A (en) 1990-08-24
WO1990008540A1 (fr) 1990-08-09
FR2643557A1 (fr) 1990-08-31
IT1237999B (it) 1993-06-21
CH683499A5 (it) 1994-03-31
IE900073L (en) 1990-07-26

Similar Documents

Publication Publication Date Title
TNSN90009A1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
HU9201700D0 (en) Oral preparations for treating internal inflammations and process for its production
DK441786D0 (da) Nucleosider, der kan anvendes terapeutisk
KR880003616A (ko) 상처치료제
FR2700117B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
EP0391088A3 (fr) Utilisation de dérivés fonctionnels de la molécule d'adhésion intercellulaire ICAM-1 dans une thérapie anti-virale
TW362973B (en) Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
FR2522664B1 (fr) Derives de fer biodisponible non dommageables au systeme gastrique, leur procede de preparation et leur application en therapeutique
IE893080L (en) Novel 2'-halomethylidene,2'-ethenylidene and¹2'-ethynyl adenosine derivatives
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
NO984572D0 (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
WO1991015200A3 (fr) Utilisation trinitrobenzenes ou d'acide carminique pour le traitement du cancer ou de maladies virales
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
FR2469711A1 (fr) Immunopotentialisateur contenant de la ricine et composition therapeutique le contenant
RU92014923A (ru) Способ лечения острой гнойной деструктивной пневмонии у детей
MY111746A (en) Therapeutic nucleosides.
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
ZA933086B (en) Novel method of treatment of Parkinson's disease
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
RU93051046A (ru) Способ борьбы с аскосферозом и гнильцовыми болезнями пчел
BE900089A (fr) Utilisation de mini-somatostatines en therapeutique.
RU94036618A (ru) Лекарственное средство для лечения железодефицитных анемий
SU1580614A1 (ru) Способ получения лектина
Bartnof Antagonism of indinavir and saquinavir confirmed
Bowersox ACTG 152: new insights into pediatric antiretroviral therapy